Prisoner #87850-053 does not get to add drug developer to his list of credits
Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 66,100+ biopharma pros reading Endpoints daily — and it's free.